9 new projects supported by the PSCC
- Voisin Céline
- Sep 25
- 1 min read
From diagnosis to therapies, from molecules to algorithms: innovation takes multiple forms within the Paris Saclay Cancer Cluster (PSCC).
This quarter, nine innovative oncology projects are joining the PSCC's BOOST program. Their diversity illustrates the breadth of the approaches supported: AI-based digital twins, liquid biopsies, nanobody therapies, next-generation immunotherapies... all pioneering solutions that strengthen the ecosystem.
The 9 new projects selected
BiPER Therapeutics – First-in-class small molecules targeting BiP to treat poor prognosis cancers.
CYBERNA – RNA biomarker signatures for early cancer detection.
Lafame – Universal digital twin in oncology, driven by artificial intelligence.
METHYS Dx – Real-time liquid biopsy tests based on DNA methylation.
NanoKur – Nanobody-based theranostic approaches linked to pathobionts.
Peekcell – AI-powered urine screening tests for women’s cancers.
Spice Bio – Reinventing immune checkpoint blocking therapies.
Syntopia – AI-augmented 3D culture systems for better drug prediction.
Tatum Biosciences – Bioengineered nanofilaments to trigger immune response.
Tailor-made support
To date, more than 70 projects have been selected by the PSCC. Each benefits from comprehensive support: scientific expertise, access to funding, networking with key stakeholders, data and sample sharing, cutting-edge technologies and infrastructure, training, and access to laboratories.
The goal: to transform pioneering ideas into concrete solutions for patients.
Apply to the BOOST program
Are you developing an innovative oncology solution? Find out how to apply via this link: Application link.
Next submission deadline: October 31, 2025.
We encourage project leaders to apply early in order to maximize their chances, through preparatory discussions with the PSCC team and, if necessary, adjustments to the file.
